Change in number of shares and votes in Episurf Medical

Episurf Medical AB (NASDAQ: EPIS B) has performed conversion of convertible bonds issued under the financing agreement published February 23, 2018. The number of convertibles converted in May was 48. The Company has now converted all outstanding convertibles during the first and only utilised tranche and intends to terminate the financing agreement with L1 Capital as previously announced. Through the conversion, the number of shares and votes increased by 2,086,956. The terms of the convertibles are published on Episurf Medical AB's website.

The total number of shares amounts to 37,200,642, of which 492,877 are A shares and 36,707,765 are B shares. The total number of votes after the conversions amounts to 38,186,396.

For more  information, please contact:

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, trough the agency of the contact person set out above, at 13:00 CEST on May 31, 2019.

Tags:

About Us

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.